Wedbush Maintains Outperform on DocuSign, Lowers Price Target to $260
Wedbush analyst Daniel Ives maintains DocuSign (NASDAQ:DOCU) with a Outperform and lowers the price target from $300 to $260.
Morgan Stanley Maintains Overweight on DocuSign, Raises Price Target to $295
Morgan Stanley analyst Stan Zlotsky maintains DocuSign (NASDAQ:DOCU) with a Overweight and raises the price target from $290 to $295.
Wells Fargo Maintains Equal-Weight on DocuSign, Raises Price Target to $215
Wells Fargo analyst Michael Turrin maintains DocuSign (NASDAQ:DOCU) with a Equal-Weight and raises the price target from $210 to $215.
24 Stocks Moving in Friday’s Pre-Market Session
Gainers
Senseonics Holdings, Inc. (NYSE: SENS) rose 37.1% to $2.81 in pre-market trading after the company disclosed results from a PROMISE study evaluating its Eversense CGM System for up to 180 days. The Eversense CGM is a continuous glucose monitoring device.
Oppenheimer Maintains Outperform on DocuSign, Lowers Price Target to $260
Oppenheimer analyst Brian Schwartz maintains DocuSign (NASDAQ:DOCU) with a Outperform and lowers the price target from $300 to $260.
10 Stocks Moving In Thursday’s After-Hours Session
Gainers
Five Below (NASDAQ: FIVE) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results and issued Q2 EPS and sales guidance above estimates.
DocuSign: Q1 Earnings Insights
Shares of DocuSign (NASDAQ:DOCU) rose in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 266.67% over the past year to $0.44, which beat the estimate of $0.28.
DocuSign Q1 Adj. EPS $0.44 Beats $0.28 Estimate, Sales $469.10M Beat $437.81M Estimate
DocuSign (NASDAQ:DOCU) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.28 by 57.14 percent. This is a 266.67 percent increase over earnings of $0.12 per share from the same